Based on industry sources, Bristol-Myers Squibb is in play and at least three potential suitors could be eyeing the prize.
Bristol-Myers Squibb stock has been hammered of late, in part on a major setback for Opdivo plus Yervoy in first-line lung cancer – now shareholders are clamoring for the company to put the “for sale” sign up. Roche Holdings, Novartis and Pfizer are thought to be kicking the tires and Gilead Sciences is also seen as a potential suitor.
While many Bristol-Myers shareholders would likely welcome a sale, it is unclear if Bristol-Myers Squibb board is ready to entertain offers. A deal, if pursued, could be valued at as much as $120 billion, or $72 per share, sources said.
The deal speculation also follows recent talks between the US pharmaceutical lobbyists and President Trump as the US government seeks possible avenues designed to reduce the costs of drugs. As Trump comes to realize he cannot rule strictly by issuing executive orders he may need to concede some testing rights for the big drug companies, such a reducing the time required to bring new drugs to market. Recall Newsweek’s comments back on February 3: “Trump wooed the attending CEOs – representing six drug makers plus the Pharmaceutical Research and Manufacturers of America, the industry’s chief lobbying organization – with promises of speeding up the process of bringing new drugs to market and removing regulations that deter companies from manufacturing drugs stateside. ‘You can’t get approval for a new plant, you can’t get approval for a new drug,’ he said. ‘So we’re going to take care of that.'”
Speculators think moves by Trump could force buyers to take a harder, longer look at Bristol-Myers given potential benefits in a trade-off with the Trump administration.
Bristol-Myers representatives have not responded to multiple requests for comment. Novartis spokesperson Eric Althoff said he would not speak to the interest in Bristol-Myers, although Althoff did address the meeting with Trump telling, saying his team “…left the meeting optimistic that we can work with the new Trump administration to ensure the U.S. continues to foster innovation and allows our industry to deliver breakthrough medicines that extend and enhance people’s lives, reduce healthcare costs and improve public health.”
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”